Stock HRGN HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Harvard Apparatus Regenerative Technology Inc.

Equities

HRGN

US09074M2026

Market Closed - OTC Markets
Other stock markets
 13:39:40 2024-04-25 EDT 		5-day change 1st Jan Change
2.39 USD +3.02% Intraday chart for Harvard Apparatus Regenerative Technology Inc. +3.02% -52.10%
04-15 Harvard Apparatus Regenerative Technology Inc. announced that it expects to receive $1.482101 million in funding CI
03-28 Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Harvard Apparatus Regenerative Technology Inc. announced that it expects to receive $1.482101 million in funding
CI
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Harvard Apparatus Regenerative Technology : March 19, 2024 - Investor Presentation
PU
Harvard Apparatus Regenerative Technology : Q4 - 2023 HBIO Quarterly Earnings Presentation
PU
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Transcript : Harvard Apparatus Regenerative Technology Inc., Q3 2023 Earnings Call, Nov 13, 2023
Harvard Apparatus Regenerative Technology : Northland Capital Markets Institutional Investor Conference 2023
PU
Harvard Apparatus Regenerative Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Transcript : Harvard Apparatus Regenerative Technology Inc., Q2 2023 Earnings Call, Aug 14, 2023
Harvard Apparatus Regenerative Technology : Q2 - 2023 HBIO Quarterly Earnings Presentation
PU
Biostage Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease
AQ
Biostage, Inc. Activated Mayo Clinic as the First Site for Clinical Trial in Severe Esophageal Disease
CI
Transcript : Biostage, Inc. - Special Call
Purcell & Lefkowitz LLP Is Investigating Biostage, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
PR
Biostage to Host Investor Call
PR
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease
AQ
Biostage, Inc. Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease
CI
Biostage Initiates Study Start-Up Activities for Clinical Trial in Severe Esophageal Disease
CI
Biostage, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Biostage, Inc. announced that it has received $6.005802 million in funding
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HRGN Stock
  4. News Harvard Apparatus Regenerative Technology Inc.